Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VDA-1102 in Actinic Keratosis
NCT03538951Phase 2Completed
- Sponsor
- Vidac Pharma
- Start
- May 2018
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tuvatexib in actinic keratosis (AK), sponsored by Vidac Pharma. Started May 2018; status: completed.
02
Drugs
tuvatexib
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on NCT03538951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03538951.